What is Lipavil used for?

Lipavil is indicated for Hyperlipidemia.

What development phase is Lipavil in?

Lipavil is FDA-approved (marketed).

What is the generic name of Lipavil?

CLOFIBRATE is the generic (nonproprietary) name of Lipavil.

Last reviewed 2026-04-20 · How we verify

Lipavil (CLOFIBRATE)

FDA-approved withdrawn Small molecule Quality 30/100

Lipavil (CLOFIBRATE) is a small molecule drug that targets the peroxisome proliferator-activated receptor alpha (PPAR-alpha). It was originally developed and is currently owned by various companies. Lipavil is a clofibrate drug class, approved by the FDA in 1967 for the treatment of hyperlipidemia. It is available as a generic medication with multiple manufacturers and is off-patent. Key considerations include its high bioavailability of 95%.

At a glance

Generic name	CLOFIBRATE
Drug class	clofibrate
Target	Peroxisome proliferator-activated receptor alpha
Modality	Small molecule
Therapeutic area	Metabolic
Phase	FDA-approved
First approval	1967

Approved indications

Hyperlipidemia

Common side effects

No common side effects on file.

Drug interactions

dicoumarol
phenprocoumon
simvastatin
warfarin

Key clinical trials

Coronary Drug Project (PHASE3)
Coronary Drug Project Mortality Surveillance (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results